Objective The objective of this study was to compare the cost effectiveness of first-line
epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) for the treatment of …

Objectives To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and
osimertinib in patients with non-small cell lung cancer (NSCLC) harbouring epidermal …

Background Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancers and
is associated with a poor prognosis. Afatinib is an irreversible ErbB family blocker …

Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small
cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase …

Gefitinib, erlotinib, afatinib and osimertinib have been recommended as the first-line
treatment for epidermal growth factor receptor (EGFR)-mutated advanced non-small cell …

Abstract Introduction The irreversible ErbB family blocker afatinib and the reversible EGFR
tyrosine kinase inhibitor gefitinib were compared in the multicenter, international …

Aim To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib,
afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC …

Purpose Tyrosine kinase inhibitors (TKI) of the epidermal growth factor receptor (EGFR) are
becoming the standard treatments for Chinese patients with advanced non-small cell lung …

Introduction Comparison of the effectiveness and cost-effectiveness of three first-line EGFR-
tyrosine kinase inhibitors (TKIs) would improve patients' clinical benefits and save costs …

Introduction Tyrosine kinase inhibitors (TKIs) therapy targets at epidermal growth factor
receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC). We aimed to …